Dr Roel Schaapveld Netherlands

InteRNA Technologies is a Dutch drug discovery and development company engaged in the development of novel breakthrough cancer therapies based on the unique functions of its proprietary miRNAs.

InteRNA well equipped to move quickly towards the clinic

InteRNA's drug development programs aim at developing miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes that are known to play a role in cancer initiation, progression and metastasis.

InteRNA identified the function of multiple miRNAs in a number of cancer indications through functional screens, using its proprietary lentiviral-based miRNA expression library, which is the largest currently available.

With the Company's proprietary miRNA expression database (generated through deep sequencing) and additional technologies (like RNAseq, PAR-CLIP, bioinformatics, in vivo models) in place to identify the downstream regulated proteins for each miRNA drug candidate, the Company is well equipped to move its novel drug candidates with their biomarkers quickly towards the clinic.

InteRNA Technologies BV
Chief Executive Officer 

Hans T. Schambye

Galecto Biotech AB
CEO 

Guus Scheefhals

Targeting toxic oligomers in misfolded protein diseases is the basis for Crossbeta’s stable oligomer drug discovery platforms which are accessible for partnering in therapeutic areas such as Alzheimer´s, Parkinson’s, Huntington and Diabetes Type 2.

In our Alzheimer program we have recently completed a high throughput screening campaign with 100,000 compounds resulting in the selection of 5 hit classes with >50%  neutralizing effect on oligomer-induced neurotoxicity.

Stable oligomers can also be used as reference in biomarker assays.

Guus Scheefhals
Crossbeta Biosciences
CEO 

Dr Roman Schenk Austria

RECARDIO is an Austrian based life science company founded in 2011. It is focusing on regenerative therapeutic modalities for the treatment of cardiovascular diseases. After establishing proof-of-principle in vivo, it is developing multiple therapeutic leads as the future regenerative medication for patients with various cardiovascular diseases, with the potential of improving their cardiac function, quality of life and survival.  
Website:
www.recardio.eu
Keywords
RECARDIO GmbH
CEO 

Monique Schiersing

Roche Venture Fund
Investment Director 

Jakob Schlapbach

Delenex Therapeutics AG
CFO 
Athera Biotechnologies AB
CEO 

Wolfgang Schoenfeld

Curadis GmbH
Business Development 

Markus Schwaller

Bachem AG
Business Development Manager 

Heinz Schwer

MorphoSys AG
Senior Director